Form 4: Upstream Bio Director Receives Stock Option Grant

Director Liam Ratcliffe was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Summary

• Director Liam Ratcliffe received a grant of 17,096 stock options.
• The options have an exercise price of $6.69 per share.
• The grant date is June 9, 2026, with an expiration date of June 8, 2036.
• The options vest in full on the earlier of June 9, 2027, or the date of the next Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is subject to market volatility and the future performance of Upstream Bio's common stock.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The vesting schedule of one year is consistent with typical annual equity refresh grants for board members in mid-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Upstream Bio, UPB, Form 4, Director Compensation, Stock Options, Insider Trading